Investor Presentation Q1-Q3 2020
43
Investor presentation
First nine months of 2020
Novo Nordisk®
Icodec, a once-weekly insulin, improved PPG control, HbA1c, and
increased the number of patients reaching target in a phase 2 trial
FPG
Icodec showed statistically significant
post prandial blood glucose control
(mmol/L)
9
8
7
6
16
5
4
*
*
W
Breakfast
+90 min
Icodec
Lunch
+90 min
Evening meal
The proportion of patients on icodec
reaching HbA1c targets was higher
Icodec
72%
75%
68%
Glargine U100
Numerical improvement in HbA1c
over 26 weeks
Glargine U100
Change
Icodec
in HbA1c
Glargine U100
Proportion
of patients
0.0
100%
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
+90 min
Bedtime
04:00
Breakfast next day
-1.4
-1.6
0 48 12 16
Weeks
20
20
0%
26
< 7.0%
≤ 6.5%
HbA1c target
*Statistically significant at week 26
PPG: Post-prandial control; FPG: Fasting plasma glucose
50%
-1.15
25%
-1.33
49%
39%View entire presentation